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Atrial ﬁbrillation (AF) has been gaining much attention as one of
the major causes of cerebral infarction [1]. For practitioners to
effectively manage this risk, it is imperative to establish an antith-
rombotic treatment for AF patients. To date, guidelines for antithrom-
botic treatment in the management of AF patients have been
published in the United States [2,3], Europe [4,5], Australia [6], Canada
[7,8], and Japan [9], which include veriﬁcation of the efﬁcacy of direct
thrombin and factor Xa inhibitors. A look at the needs of patient
populations in the Asia-Paciﬁc region shows that antithrombotic
treatment has not yet been deﬁned and no such guidelines exist.
The Asia Paciﬁc Heart Rhythm Society (APHRS)—Practice Guideline
Subcommittee conducted a Web-based survey from June 2011 to
August 2011 to elucidate the current status of antithrombotic treat-
ment in 9 countries. When research was completed, the APHRS
published a report entitled, “Fact-ﬁnding survey of antithrombotic
treatment for prevention of cerebral and systemic thromboembolism
in patients with non-valvular atrial ﬁbrillation in 9 countries of the
Asia-Paciﬁc region” in the Journal of Arrhythmia [10].76/$ - see front matter & 2013 Japanese Heart Rhythm Society. Published by Els
x.doi.org/10.1016/j.joa.2013.03.002
esponding author.
ail address: sogawa@iuhw.ac.jp (S. Ogawa).
HRS Practice Guideline Subcommittee member.The survey revealed substantial differences in antithrombotic
treatments among the 9 surveyed countries. Although the overall
survey size was small, in that only 50 physicians per country
participated, and further research is still necessary, we believe that
the results provide a good foundation to continue the process of
creating usable, safe antithrombotic treatment guidelines for patients
in Asia-Paciﬁc countries. Among the many results noted in the survey
are as follows: (1) there were large differences in the stance of using
antiplatelet agents for low-risk patients with a CHADS2 score of 0–1;
(2) warfarin was markedly underused in some countries; and (3)
warfarin was quickly replaced by dabigatran, such that dabigatranwas
more frequently used than warfarin in some countries.
Since antithrombotic therapy for patients with AF is rapidly
changing with the increasing use of dabigatran, rivaroxaban, and
apixaban, some of the primary issues that will inﬂuence the future
revision of various guidelines (HRS [Heart Rhythm Society], ESC
[European Society of Cardiology], ACC [American College of Car-
diology], CCS [Canadian Cardiovascular Society], JCS [Japanese
Circulation Society], etc.) would be how to use warfarin and
other drugs for different indications and to determine the most
accurate clinical position of each drug. In particular, there are data
currently suggesting that the bleeding risk associated with newer
anticoagulants is lower than that of warfarin [11–14]. Therefore, a
central point in the new guidelines or statements would be to
expand the indications of these newer anticoagulant drugs toevier B.V. All rights reserved.
S. Ogawa et al. / Journal of Arrhythmia 29 (2013) 190–200 191include low-risk patients (CHADS2 score 0/1) and to reconsider the
indications of antiplatelet agents, including acetylsalicylic acid (ASA).
Under such circumstances, it is mandatory to publish the
APHRS's “Statement on antithrombotic therapy of AF” with the
aim of unifying the variety of antithrombotic therapies in Asia-
Paciﬁc countries and promoting the appropriate use of antic-
oagulants, including newly launched drugs.2. Current status of international guidelines after launch of
novel anticoagulants
When developing guidelines on antithrombotic therapy, we must
consider that novel anticoagulants are approved in differentTable 1
Approval status of 4 novel oral anticoagulants in Asia-Paciﬁc countries at the end of
December 2012.
Dabigatran Rivaroxaban Apixaban Edoxaban
Australia ○ ○  
Brunei    
China ○* ○*  
Hong Kong ○ ○  
India ○   
Indonesia ○ ○  
Japan ○ ○ ○ ○*
Korea ○ ○  
Macao ○ ○  
Malaysia ○ ○  
New Zealand ○ ○*  
Philippines ○ ○  
Pakistan    
Singapore ○ ○  
Taiwan ○ ○  
Thailand ○   
Vietnam ○   
(Dec 2012) ○: approved; ○*: approved for DVT.
Table 2
Summary of recommendations proposed by JCS 2008, ESC 2010, Australian 2011, ACCP
CHADS2Z2 CHADS2 ¼ 1
JCS 2008
(with urgent
statement 2011)
Warfarin
Dabigatran
Dabigatran
(Warfarin can be
considered)
ESC 2010 Warfarin
Dabigatran
Z2
OAC
Aus 2011 Warfarin Warfarin/ASA
ACCP 2012 Warfarin
Dabigatran
OAC 4 ASA
CCS 2012 OAC OACb
Dab/Riv/Api 4 Warfarin
Abbreviations: OAC, oral anticoagulants; ASA, acetylsalicylic acid; No Tx, no treatment;
a Cardiomyopathy, 65 to 74 years of age, female sex, coronary artery disease or thyr
b ASA is a reasonable alternative.countries at different times. Since the primary role of guidelines is
to describe how to use currently available drugs, guidelines used in a
country should describe regimens of drugs currently available in
that country. However, the approval status of dabigatran, rivarox-
aban, apixaban, and edoxaban as of the end of 2012 differs among
Asia-Paciﬁc countries (Table 1), and this may pose a problem in
establishing a common guideline document for those countries.
Table 2 lists current guidelines for antithrombotic therapy in AF.
The Joint Working Groups for the Guidelines for Pharmacotherapy of
Atrial Fibrillation (JCS 2008, referred to as the “JCS 2008” guidelines
hereinafter) [9] published an urgent statement on antithrombotic
therapy of AF in 2011 after the launch of dabigatran in Japan [15]. The
ESC 2010 guidelines for the management of AF (referred to as the
“ESC 2010” guidelines) [4] recommend risk stratiﬁcation according to
the CHADS2 score, and recommend the CHA2DS2-VASc score in low-
risk patients with a CHADS2 score of 0/1. Although all relevant
guidelines describe that oral anticoagulants (OACs) are indicated for
patients with a CHADS2 score of ≥2, the indication differs across
guidelines. The ESC 2010 guidelines describe that dabigatran may be
considered an alternative to warfarin; the “Quick Reference Guide:
Atrial Fibrillation Information for the Health Practitioner” proposed by
the government of Western Australia (referred to as the “Australian
2011” guidelines) [6] lists warfarin only; the evidence-based clinical
practice guidelines for antithrombotic therapy for AF proposed by the
American College of Chest Physicians (referred to as the “ACCP 2012”
guidelines) [3] made recommendations only for dabigatran, which
was approved for use in AF, among novel OACs as an alternative to
warfarin; and the focused 2012 update of the CCS AF guidelines
(referred to as the “CCS 2012” guidelines) [8] suggest that when
OAC therapy is indicated, most patients should receive dabigatran,
rivaroxaban, or apixaban in preference to warfarin, since all these
drugs are associated with less intracranial hemorrhage (ICH) and
are much simpler to use. However, the CCS 2012 guidelines describe
that the preference for one of the novel OACs over warfarin is less
marked among patients already receiving warfarin with stable inter-
national normalized ratio (INR) and no bleeding complications. The
ESC 2012 focused update guidelines [5] use a description of novel
OACs to include apixaban, which was not approved yet at the time of
revision.2012, and CCS 2012.
CHADS2 ¼ 0
Other risk factorsa No risk factor
Warfarin/Dabigatran
can be considered
No Tx
CHA2DS2-VASc score
1 0
OAC/ASA No Tx/ASA
ASA
No Tx 4 ASA
65-74 y/0
F+Vasc
F
Vasc
0
OACb ASA No Tx
F, female; Vasc, vascular diseases; Dab, dabigatran; Riv, rivaroxaban; Api, apixaban.
otoxicosis.
Table 3
Summary of recommendations proposed by ESC 2012 and APHRS 2013.
ESC 2012
CHA2DS2-VASc score
≥2 1 0
NOAC NOAC No Tx
W (alternative)
APHRS 2013
CHA2DS2-VASC score
≥2 1 0
OAC (D/R/A/W) NOAC (D/A) No Tx
W/R (alternative)
Abbreviations: NOAC, novel oral anticoagulants; OAC, oral anticoagulants; W, warfarin;
D, dabigatran; R, rivaroxaban; A, apixaban; No Tx, no treatment.
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(Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared
with Vitamin K Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation) trial, patients with a CHADS2 score of ≥2
were investigated and thus rivaroxaban should be indicated for this
population of patients. The JCS's urgent statement [15] recommends
that factor Xa inhibitors currently under development will be
included as drugs “recommended” or “can be considered” for use
according to the CHADS2 score of patients evaluated in clinical trials.
On the basis of this consideration, the JCS's urgent statement placed
dabigatran as a drug of choice for patients with a CHADS2 score of
1 and warfarin as a drug that “can be considered.”
As Table 2 shows, all guidelines recommend OACs for patients
with a CHADS2 score of ≥2, whereas recommendations for low-
risk patients with a CHADS2 score of 0/1 differ slightly across
guidelines. Evidence indicating that novel OACs decrease the risk
of ICH by half as compared with warfarin has affected the
recommendations of guideline documents. The ESC 2010 guide-
lines are the ﬁrst among the guidelines reviewed to introduce the
CHA2DS2-VASc score, and recommend physicians to classify low-
risk patients with a CHADS2 score of 0/1 into 3 subgroups. In the
CHA2DS2-VASc score, the major risk factors (2 points) are prior
stroke or transient ischemic attack (TIA), and older age (≥75
years), and the clinically relevant nonmajor risk factors (1 point)
are heart failure, hypertension, diabetes mellitus, female sex, age
65−74 years, and vascular disease. The ESC 2010 guidelines
recommend OAC for patients with a CHA2DS2-VASc score of ≥2,
OAC or ASA (OAC is more preferable) for patients with a score of 1,
and no treatment or ASA for those with a score of 0 (no treatment
is more preferable). Dabigatran is the OAC of choice. The JCS 2008
guidelines adopted a similar concept, and describe that physicians
may consider warfarin and dabigatran for patients with risk
factors other than those used in the CHADS2 score, such as age
65−74 years, female sex, and having coronary artery disease as
those with a CHADS2 score of 1. The Australian 2011 guidelines and
the ACCP 2012 guidelines use the CHADS2 score but differ slightly
in treatment for patients with a CHADS2 score of 0 and 1. On the
other hand, the CCS 2012 guidelines use the concept of the
CHA2DS2-VASc score but weigh factors in a way different from
those in the ESC 2010 guidelines. The CCS 2012 guidelines weighed
factors that were deﬁned as clinically relevant nonmajor factors in
the ESC 2010 guidelines differently, and recommend the following
treatment for patients with a CHADS2 score of 0: OAC for those
65–74 years of age or female patients with vascular disease; ASA
for female patients or those with vascular disease; and no treat-
ment for male patients o65 years old. The CCS 2012 guidelines
recommend OAC for patients with a CHADS2 score of 1. In all cases,
ASA is recommended as an alternative to warfarin.
As mentioned above, there is a slight difference among guidelines
in handling female sex as a risk factor in the assessment of low-risk
patients by using the CHA2DS2-VASc score. As Table 3 shows, the ESC
2012 focused update guidelines [5] recommend the use of the
CHA2DS2-VASc score in the assessment of all patients, including
high-risk patients. However, the ESC 2012 focused update guidelines
recommend “no antithrombotic therapy” for patients “o65 years
and lone AF (including females)” since the risk of stroke is considered
low in this patient population [16]. In the CHA2DS2-VASc score,
“female sex” is a clinically relevant nonmajor risk factor with a
CHA2DS2-VASc score of “1,” although female patients may be
considered at low risk if they are “under 65 years of age.” Female
patients ≥65 years of age should have a CHA2DS2-VASc score of 2,
and they are recommended to receive OAC. The present APHRS
statement uses similar criteria for female patients.
In the APHRS survey, we assessed the use of the CHA2DS2-VASc
score in the 9 member countries [10]. A questionnaire survey
conducted in June to August 2011 revealed that 47% and 45% ofphysicians are using the CHADS2 and CHA2DS2-VASc scores, respec-
tively. The CHA2DS2-VASc score is used by more than half of the
respondents in New Zealand (86%), India (59%), Singapore (57%),
and Australia (54%), whereas the CHADS2 score is widely used in
Japan (70%), Hong Kong (61%), and Taiwan (57%). Since evidence has
shown the superiority of the CHA2DS2-VASc score, and its use is
recommended in many countries, the APHRS decided to recom-
mend the use of this score in the guideline. Both cardiologists and
general practitioners in the Asia-Paciﬁc region should be encour-
aged to use the CHA2DS2-VASc score as a basic risk assessment
method for selecting better anticoagulation therapy.
Friberg et al. [17] have indicated that the CHA2DS2-VASc score is
superior to the CHADS2 score in terms of stroke risk stratiﬁcation,
and the risk of stroke is extremely low among patients with a
CHA2DS2-VASc score of 0 in whom antithrombotic therapy is not
beneﬁcial and may even increase the risk of ICH. They proposed that
antithrombotic therapy should be performed in all patients with AF
other than those with a CHA2DS2-VASc score of 0 and those with a
high risk of bleeding (e.g., patients with a history of massive bleeding
and patients with malignant hypertension). They expect that more
patients will be indicated for antithrombotic therapy when novel
OACs become more available as alternative agents to warfarin.
In the absence of head-to-head comparative studies, it is
difﬁcult to conclude that the 3 novel OACs (dabigatran, rivarox-
aban, and apixaban) are equally useful. In an indirect model
analysis, Banerjee et al. [18] concluded that the 3 novel OACs have
net clinical beneﬁts higher than warfarin in patients at high risk of
bleeding and stroke. These drugs were shown to be superior
(150 mg bid dabigatran, apixaban) or noninferior (rivaroxaban)
to warfarin in the prevention of stroke (for ischemic stroke
prevention, a true efﬁcacy parameter as AF causes ischemic and
not hemorrhagic stroke, only dabigatran was shown to be super-
ior), and have lower risk of ICH than warfarin. When the net
beneﬁt of new drugs is clariﬁed in the future, it is expected that
antithrombotic therapy will also be indicated for patients with a
lower risk of stroke than those currently indicated for warfarin.
However, dabigatran at 150 mg bid was associated with an
increased risk of extracranial bleeding in patients aged 75 years or
older [19]. In patients o75 years of age, 110 and 150 mg bid
dabigatran were superior and comparable to warfarin, respec-
tively, in terms of the risk of major bleeding. In the ROCKET AF
trial, the risk of bleeding from gastrointestinal sites, including
upper, lower, and rectal sites, was higher among patients receiving
rivaroxaban than those receiving warfarin [13]. In a subanalysis of
the ROCKET AF trial, rivaroxaban was comparable to warfarin in
terms of the risk of bleeding in elderly patients [20]. Both apixaban
and rivaroxaban required a dose reduction to 2.5 mg bid and
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moderate renal dysfunction (creatinine clearance 30–50 mL/min,
and in case of apixaban, 2.5 mg bid for a subset of patients with
2 or more of the following criteria: age 480 years, body weight
o60 kg, serum creatinine 41.5 mg/dL). In the case of dabigatran,
both doses were used in patients with mild to moderate renal
dysfunction, and in a subgroup analysis of age and renal dysfunc-
tion it was shown that the 110 mg bid dose may be considered in
patients with a creatinine clearance of 30–50 mL/min.
Since patients with AF must continue antithrombotic therapy
for the duration of their life, the safety of new antithrombotic
agents in elderly patients is particularly important. Considering
the racial/ethnic differences in bleeding, it may be preferable in
Asia-Paciﬁc countries that patients 475 years of age should
receive warfarin as the ﬁrst-line therapy, and patients 470 years
of age should have INR 1.6–2.6, as recommended by the JCS 2008
guidelines. Alternatively, elderly patients (480 years old) should
receive dabigatran at the 110 mg bid dose, whereas in those
between 75 and 80 years of age the 110 mg bid dose may be
considered if they also have 1 or more risk factors for bleeding.
Aging is known as the biggest risk factor of stroke and warfarin-
associated bleeding. However, Singer et al. [21] have reported that
the net clinical beneﬁt of warfarin increased consistently with age,
and was highest among patients 485 years of age. Friberg et al. [17]
have reported that the net clinical beneﬁt of warfarin is maintained
even when the risk of ICH is assumed to double the risk of stroke.
These ﬁndings support that warfarin is important to ensure effective
prevention of stroke among elderly patients even when this drug
increases the risk of bleeding in this patient population.
Another problem is that the indications of each drug differ
among Asia-Paciﬁc countries, and it is difﬁcult to provide recom-
mendations that are consistent with the indications in each
country. For example, in Japan, the 3 novel OACs are indicated
for “the prevention of ischemic stroke and systemic embolism in
patients with nonvalvular AF” regardless of the results of the risk
assessment according to the CHADS2 score. The National HealthFig. 1. Awareness of CHA2DS2-VASC score for risk stratiﬁcation.
Adapted from Ogawa et al. [10], with permission from Elsevier.Insurance system in Japan covers the use of these drugs even
when they are prescribed to patients with a CHADS2 score of 0.
According to these circumstances, the APHRS 2013 statement
(Table 3) lists dabigatran, rivaroxaban, and apixaban separately,
and describes the use of each of these drugs with warfarin in order
to help physicians in Asia-Paciﬁc countries prescribe these drugs
appropriately, to ensure optimal anticoagulant therapy in each
patient when these drugs are approved in the relevant country.
We hope that physicians will make the most of the statement in
accordance with the health-care policy in each country.3. Positioning of ASA
Another important point in Table 2 is that the weight of ASA
differs across different guidelines. While the JCS 2008 guidelines
do not recommend ASA for patients with AF and the CCS 2012
guidelines do not recommend ASA for patients with a CHADS2
score of 0 and without clinically relevant nonmajor factors, other
guidelines recommended ASA for patients with a CHADS2 score of
0/1. Since it has been reported that bleeding complications of ASA
are more common in Asian patients [22,23], guidelines appro-
priate for patients in Asia-Paciﬁc countries are awaited.
The ESC 2010 and CCS 2012 guidelines recommend HAS-BLED
(Hypertension, Abnormal renal/liver function, Stroke, Bleeding
history or predisposition, Labile INRs, elderly [≥65], and drugs/
alcohol concomitantly) as an indicator of the risk of bleeding. ASA
rather than warfarin has tended to be recommended for patients
with a high risk of bleeding. It is difﬁcult to assess the net beneﬁt
of antithrombotic therapy in elderly patients in whom the risks of
stroke and bleeding are high. However, the recently reported
results of the Danish National Patient Registry [24] did not support
a favorable net clinical beneﬁt of ASA monotherapy in patients
with a high risk of bleeding. These ﬁndings suggest that guidelines
for patients in Asia-Paciﬁc countries should not recommend ASA,
as the JCS 2008 guidelines do not.
S. Ogawa et al. / Journal of Arrhythmia 29 (2013) 190–200194The ESC guidelines have issued a 2012-focused update [5] and
clearly denied the use of ASA for patients with CHA2DS2-VASc
score of 0. ASA should be considered in patients who refuse any
OAC, or cannot tolerate anticoagulants.
In the APHRS 2013 statement, we propose that ASA is not
recommended in principle.Fig. 2. Antithrombotic strategy according to CHADS2 score.
Adapted from Ogawa et al. [10], with permission from Elsevier.
Fig. 3. Antithrombotic strategy for patients with no risk factors (CHADS2¼0).
Adapted from Ogawa et al. [10], with permission from Elsevier.4. Use of antithrombotic agents by CHADS2 score: results of the
APHRS survey
As Fig. 1 shows, the results of the APHRS survey revealed
differences among physicians in the 9 participating countries in
terms of the dependency on the CHADS2 and CHA2DS2-VASc
S. Ogawa et al. / Journal of Arrhythmia 29 (2013) 190–200 195scores in risk assessment of patients with AF. More than 50% of
physicians in Australia, India, New Zealand, and Singapore are
using the CHA2DS2-VASc score, whereas users of the CHADS2 score
accounted for ≥50% in Japan, Taiwan, and Hong Kong. Of note, 70%
of physicians in Japan use the CHADS2 score, whereas 86% of
physicians in New Zealand use the CHA2DS2-VASc score to assess
the risk of AF patients.Fig. 4. Antithrombotic strategy for patients with 1 risk factor (CHADS2¼1).
Adapted from Ogawa et al. [10], with permission from Elsevier.
Fig. 5. Antithrombotic strategy for patients with 42 risk factors (CHADS2¼2 or more)
Adapted from Ogawa et al. [10], with permission from Elsevier.Considering the underuse of OACs and the overuse of ASA among
patients with a CHADS2 score of 0/1 (see below for detail), the
CHA2DS2-VASc score should be adopted in the APHRS's statement.
The use of antithrombotic therapy according to the CHADS2
score differed signiﬁcantly among the 9 countries (Figs. 2–5).
In patients with a CHADS2 score of 0 (Fig. 2), the frequency of
use of OACs (including novel OACs) was extremely low (11%), and.
S. Ogawa et al. / Journal of Arrhythmia 29 (2013) 190–200196in most cases, antiplatelet agents are used (63%). In patients with a
CHADS2 score of 1, OACs and antiplatelet agents were used by
approximately half of the physicians each (41% vs. 49%, respec-
tively). In contrast, for patients with a CHADS2 score of 2, OACs
(including warfarin, direct thrombin inhibitor, and their concomi-
tant use with antiplatelets) were used at an unexpectedly high
percentage, namely as high as 87% of the physicians.
We also looked at antithrombotic therapy for each CHADS2
score in each country. For patients with CHADS2 score of 0 (Fig. 3),
approximately 80% of the physicians used antiplatelet agents in
6 of the countries—Australia, China, Korea, Taiwan, Hong Kong,
and Singapore. A total of 59% of the physicians used antiplatelet
agents in New Zealand, and 34% (64%, if concomitant use with
OACs was included) in India. In Japan, 16% of the physicians used
antiplatelet agents (36% used OAC, 46% provided no treatment);
thus, the treatment stance in Japan is rather unique.
For patients with CHADS2 score of 1 (Fig. 4), India has a very
unique treatment stance, in that 70% of the physicians used
antiplatelet agents alone and 28% in combination. In contrast,
70% of the physicians used OACs in Japan, followed by 65% in
Singapore and 54% in New Zealand; thus, OACs are actively used
for relatively low-risk patients in these countries. In other coun-
tries, 30–50% of the physicians used OACs.
For patients with CHADS2 score of 2 (Fig. 5), the frequency of
use of OACs (including warfarin, direct thrombin inhibitor, and
their concomitant use with antiplatelets) is high (100% in Aus-
tralia, Hong Kong, New Zealand, and Singapore). Surprisingly, 50%
of physicians in India used antiplatelet agents alone. For patients
with CHADS2 score of 2 with stroke, a similar trend was observed.
It can be summarized that the frequency of use of OACs was
high in patients with a CHADS2 score of 2, in accordance with the
guidelines, except in India. The countries had different treatment
stances for low-risk patients with a CHADS2 score of 0/1. It is
important to reach a consensus on the treatment of this patient
group when preparing the APHRS's statement. In particular, in
Japan, evidence [22] that ASA use only increases the bleeding risk
and has no embolism-preventing effect is incorporated in the JCS
2008 guidelines, and follow-up without treatment or the use of
OACs, if any treatment is provided, is recommended. On the other
hand, in India, 70% of physicians use antiplatelet agents even for
patients with a CHADS2 score of 1.5. Problems with warfarin therapy
There are 2 important problems with the use of warfarin in the
clinical setting. The ﬁrst problem is underuse. Of patients with
nonvalvular AF and no known contraindications, 55% received war-
farin. Warfarin use was substantially lower in elderly patients inwhom
warfarin therapy is believed essential [25]. Many registration studies in
Europe and the United States consistently revealed underuse of
warfarin in patients with a higher risk for stroke [26–28]. In the
present survey by the APHRS, 60% of high-risk patients with a CHADS2
score of 2 received warfarin. The second problem is suboptimal
regimens among patients receiving warfarin. Patients who achieved
an optimal INR (2.0–3.0) accounted for about 50%. To maximize the
efﬁcacy of warfarin therapy, the time in therapeutic range (TTR)
should be at least 60% [29].
As the APHRS survey indicated, warfarin is signiﬁcantly underused
in India. Physicians in India may be more affected by the problems
associated with the use of warfarin as compared with those in other
Asia-Paciﬁc countries. The survey also indicated that physicians in
India do not rely on laboratory-reported INR data as the control agent
used varies from laboratory to laboratory, leading to a high coefﬁcient
of variation. If the reason for the underuse of warfarin in India is
limited to problems associated with warfarin treatment,antithrombotic therapy is expected to improve when physicians
understand the advantage of novel OACs, such as the elimination of
the need for frequent INR measurements, treatment at a ﬁxed dose,
and lesser or no clinically signiﬁcant interactions with food and other
drugs. The use of novel OACs may improve the status of warfarin
underuse, especially in patients with active lifestyles.6. Discontinuation of anticoagulants before surgery and other
invasive procedures that cause bleeding
Garcia et al. [30] discussed 2 questions: (1) For how long should
the anticoagulant be stopped before the procedure? and (2) Should a
bridging strategy be used with heparin? Since patients with AF may
be left with suboptimal protection against stroke for several days
before and after surgery during which time warfarin therapy is
suspended, bridging therapy with heparin or other drugs has been
recommended for patients with a high risk for stroke, although there
is little reliable evidence that bridging therapy beneﬁts patients with
AF. Observational studies indicate that many (if not most) AF patients
who simply interrupt warfarin for 7 days (without bridging therapy)
have a very low risk for stroke.
On the other hand, treatment with novel OACs with a half-life
of ≤12 h may be suspended immediately before surgery and
restarted promptly after surgery. Healey et al. [31] reported the
outcome of patients with AF who discontinued anticoagulant
therapy at least once for invasive procedures during the RE-LY
(Randomized Evaluation of Long-term Anticoagulation Therapy)
trial. Patients discontinued anticoagulation therapy on average
2 and 5 days before the procedure in the dabigatran and warfarin
groups, respectively, and only a portion of the patients received
periprocedural bridging therapy (28.5% in the warfarin group and
16% in the dabigatran group). Perioperative thromboembolic
events developed in only 21 of 4591 patients (0.5%), and the
incidence of postoperative bleeding complications was 4–5% with
no signiﬁcant difference between the 2 groups. The incidence of
stroke or systemic embolism was quite low both in the dabigatran
and warfarin groups after short-term discontinuation of antic-
oagulant therapy. The duration of anticoagulant discontinuation
for surgery was shorter in the dabigatran group than in the
warfarin group. These ﬁndings suggest that novel shorter-acting
OACs are more beneﬁcial in patients expected to undergo surgery
or invasive procedures that cause bleeding.
In the APHRS survey, most respondents (86%) answered that
OACs were discontinued before endoscopy or surgery. With novel
OACs, physicians will be able to discontinue anticoagulant therapy
before the surgical procedure without concern for thrombotic
complications. The APHRS survey did not investigate whether
physicians performed periprocedural bridging therapy for their
patients. The survey revealed that 56% of physicians in India
continued OAC during procedures despite the risk of bleeding. If
they continue OAC because of the fear of perioperative thrombotic
complications, discontinuation may be encouraged on the basis of
the report by Healey et al. [31], as mentioned above.
Although the bleeding risk is low during tooth extraction even
in patients continuing OAC, physicians in almost all countries,
excluding Japan, answered that they discontinued OAC before
tooth extraction. The survey revealed that 78% of the physicians
in Japan continue anticoagulation therapy during tooth extraction
but most in other countries stop the anticoagulation therapy
before the tooth extraction procedure. The risk of embolism may
increase during interruption of antithrombotic therapy, and this
leads to concern that the patients could have a risk of embolism
while the anticoagulation therapy is stopped. It has been reported
that serious thromboembolism occurs in about 1% of patients with
AF after discontinuation of warfarin [32,33]. Randomized
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tooth extraction can be safely performed on patients receiving
antithrombotic drugs [34,35].7. Racial/ethnic difference in anticoagulant effects
Shen et al. [23] investigated a stroke-free cohort of 18,867
patients who were hospitalized for nonvalvular AF (78.5% white,
8% black, 9.5% Hispanic, and 3.9% Asian). During the follow-up
period of 3.3 years, 173 patients experienced ICH. Anticoagulation
intensity (INR) was lower among blacks but not different between
the other groups. Warfarin was associated with increased ICH risk
in all races; however, the magnitude of risk was greater among
nonwhites. There were no sex differences. The hazard ratio for ICH
with whites as reference was 4.06 for Asians, 2.06 for Hispanics,
and 2.04 for blacks. It has been reported that the dose of warfarin
to achieve the same INR was the smallest in Asian patients and the
highest in black patients, and Caucasian patients were between
Asian and black patients [36,37]. It is also an important point to
discuss whether all races need the same INR to ensure the
prevention of thromboembolic events in patients with AF. You
et al. [38] have reported that an INR of 1.8–2.4 appeared to be
associated with the lowest incidence rate of major bleeding or
thromboembolic events as compared with an INR of 2–3. In the
APHRS survey, 58% of physicians answered that they set different
INR ranges for different age groups (Fig. 6), although 29% of
Australian physicians and only 10% of New Zealand physicians
adjust INR depending on age. The threshold age was 74 years on
average. As Fig. 7 shows, physicians in most countries, excluding
India, target the INR value at 2–3 in younger patients, which is
consistent with the guidelines, and at 1.6–2.6 in elderly patients.
The JCS 2008 guidelines recommend that the target INR be 2–3 for
patients o70 years of age and 1.6−2.6 for patients 470 years of
age on the basis of the results of a prospective study of elderlyFig. 6. Adjustment of the international normalized ratio according to age.
Adapted from Ogawa et al. [10], with permission from Elsevier.patients (≥70 years) in Japan in whom low-dose warfarin therapy
to target an INR of 1.6−2.6 was conﬁrmed to be safe and effective
[39]. The results of the APHRS survey indicated that all countries
used similar criteria. It is desirable that the APHRS's statement
should specify warfarin regimens for different age and racial/
ethnic groups.
A subanalysis of the RE-LY trial reported important data about
the risk of bleeding in Asian patients [40]. In a comparison
between Asian and non-Asian patients receiving warfarin, the
risks of ischemic stroke and hemorrhagic stroke were twice higher
in Asian than in non-Asian patients. It is possible that a racial or
genetic factor is involved in this difference, which has been
pointed out for years, but we should also consider other factors
because no such differences were observed in a comparison
between Asian and non-Asian patients receiving dabigatran. The
low average INR value and the low TTR in Asian patients may be
the biggest reasons for the higher risks of ischemic stroke and
hemorrhagic stroke. The subanalysis of the RE-LY trial [40]
revealed that the percentage of patients with a mean INR of o2
was 19.8% among non-Asian patients and 35.4% in Asian patients,
and the percentage of patients with a mean INR of 2–3 was 66.2%
and 54.5% in non-Asian and Asian patients, respectively. These
results suggest that Asian patients are not receiving sufﬁcient
warfarin therapy. Additionally, a comparison of the TTR among
countries participating in the RE-LY trial [41] has indicated
insufﬁcient warfarin therapy in Asian countries. In fact, TTR
exceeded 60% only in Australia (74%), Singapore (68%), and Hong
Kong (64%), whereas TTR was lower in Japan (58%), Korea (55%),
China (55%), India (49%), and Taiwan (44%) (no data were available
in New Zealand). It is plausible that this may explain the high
incidences of ischemic stroke and hemorrhagic stroke among
Asian patients. Physicians in Asian countries should be encouraged
to maintain TTR at an appropriate level (≥60%) when elderly
patients receive warfarin therapy at a low target INR level as
recommended in the JCS 2008 guidelines and this APHRS
Fig. 7. Optimal international normalized ratio for normal and aged patients.
Adapted from Ogawa et al. [10], with permission from Elsevier.
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bleeding was much lesser in the Asian than in the non-Asian
cohort in the RE-LY trial.
Racial/ethnic differences should also be considered for the
effects of ASA. In the JAST (Japan Atrial Fibrillation Stroke Trial)
in 896 Japanese patients with nonvalvular AF [22], the incidence of
the primary composite endpoint (i.e., cerebral infarction, TIA, or
cardiovascular death) was higher in patients receiving 150
−200 mg/day ASA (3.1%/year) than in patients not receiving ASA
(2.8%/year), and the incidence of serious bleeding in patients
receiving ASA was 0.8%/year, which was 4-fold the incidence in
patients not receiving ASA (0.2%/year). The JAST was discontinued
when these differences were observed in an interim analysis. The
JCS 2008 guidelines thus prohibit anticoagulation with ASA in
patients with AF.8. Anticoagulation for patients receiving warfarin in whom
INR is maintained at an optimal level
In patient groups in “good control” and “excellent control” with
warfarin, who are deﬁned as those with a TTR of 65.5−72.6% and
≥72.6%, respectively, the effects of warfarin therapy in preventing
stoke was similar to 150 mg bid dabigatran [41]. The risk of major
gastrointestinal bleeding was twice higher in patients receiving
dabigatran than those receiving warfarin, and the incidence of ICH
was lower in those receiving dabigatran. According to these
ﬁndings, the American College of Cardiology Foundation/American
Heart Association (ACCF/AHA) Task Force on practice guidelines
[42] published a supplementary report on the use of dabigatran
and recommended dabigatran for the prevention of stroke in
patients with AF (Class I, Level of Evidence: B), although “patients
already taking warfarin with excellent INR control may have little
to gain by switching to dabigatran.”9. Anticoagulation therapy for patients with paroxysmal AF
and persistent AF
In International guidelines, there are no differences in the
content of anticoagulation therapy between patients with par-
oxysmal AF and persistent AF because the risk of stroke is
similar between these patient groups. However, the APHRS survey
revealed that physicians in China, India, Korea, and Taiwan do not
follow this recommendation. When physicians were asked, “Is
antithrombotic therapy similar to that given to persistent AF
patients provided also to paroxysmal AF patients?,” on average
in the 9 countries, 68% of the physicians answered yes: 74−91%
answered yes in Japan, Singapore, Hong Kong, Australia, and New
Zealand, whereas only 50−62% answered yes in China, India,
Korea, and Taiwan. The APHRS's statement will describe that
patients with paroxysmal AF should receive antithrombotic ther-
apy similarly to patients with persistent AF.10. OAC in patients receiving elective deﬁbrillation
In a subanalysis of patients with nonvalvular AF who under-
went deﬁbrillation during the RE-LY trial [43], the incidence of
stroke or systemic embolism during the ﬁrst 30 days after
deﬁbrillation was low both in the warfarin and dabigatran groups.
However, there are no alternatives that may replace the interna-
tional recommendation stating that “warfarin therapy should be
continued for 3 weeks prior to and 4 weeks following elective
deﬁbrillation.” In the APHRS survey, patients with paroxysmal and
persistent AF were treated similarly. In fact, 72−100% of the
physicians used warfarin/dabigatran as monotherapy or combina-
tion with antiplatelet agents for patients with persistent AF, and
there were scarce differences among the countries. However, it
may be a problem that as many as 28% of the physicians prescribe
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cardioversion in India.11. Recommendations from APHRS on antithrombotic
treatment for nonvalvular AF
On the basis of the latest trends in antithrombotic therapy
worldwide and the current practices of antithrombotic therapy
observed in the APHRS survey, we propose the following recom-
mendations (Table 3).11.1. The CHA2DS2-VASc score should be used to assess
the risk of stroke
The ESC 2012 guidelines adopted a CHA2DS2-VASc score for risk
stratiﬁcation, and recommend novel OACs (warfarin is an alter-
native) for patients with a CHA2DS2-VASc score of ≥2 and 1, and no
treatment for those with a score of 0. It is characterized that ASA is
not recommended in this focused update. In the CHA2DS2-VASc
score, the major risk factors (2 points) are prior stroke or TIA, and
older age (≥75 years), and the clinically relevant nonmajor risk
factors (1 point) are heart failure, hypertension, diabetes mellitus,
female sex, age 65−74 years, and vascular disease.
In the APHRS's 2013 statement, patients should be classiﬁed
into 3 groups, i.e., patients with a CHA2DS2-VASc score of ≥2, 1,
and 0. Patients with a CHA2DS2-VASc score of ≥2 should receive
OAC (3 novel OACs or warfarin), those with a score of 1 should
receive novel OACs excluding rivaroxaban, and those with a score
of 0 should receive no treatment. Rivaroxaban can be considered
an alternative in patients with a score of 1 since the effect and
safety of rivaroxaban were evaluated in the ROCKET AF trial only in
patients with CHADS2 score of ≥2.
Similarly to the ESC 2012 focused update guidelines, female
patients with sex alone as a single risk factor (still a CHA2DS2-VASc
score of 1) should be regarded as those with a score of 0.11.2. In principle, any of the 3 novel OACs should be used for patients
with a CHA2DS2-VASc score of ≥2 and 1
Warfarin can be prescribed for patients with a CHA2DS2-VASc
score of ≥2 and be optional for patients with a CHA2DS2-VASc
score of 1 (based on the APHRS survey in patients with a CHADS2
score of 1 in that warfarin was prescribed by 34% of physicians).
Warfarin should be used for the following patients:a. Patients with artiﬁcial valve replacement and patients with
rheumatic valvular disease.b. Patients who achieved adequate INR control with warfarin and
have no bleeding complications.c. Elderly patients (≥75 years of age). Warfarin may be replaced
by low-dose dabigatran therapy.
11.3. Optimal INR of warfarin
International guidelines recommend that the optimal INR of
warfarin is 2.0−3.0. Since the JCS 2008 guidelines recommended
an INR of 1.6−2.6 for patients ≥70 years of age, which does not
substantially differ from practices in Asia-Paciﬁc countries
(excluding Australia and New Zealand, as shown in Fig. 6), we
recommend an INR of 1.6–2.6 for patients ≥70 years of age.
However, it is essential to maintain TTR at ≥60% to ensure the
prevention of both ischemic stroke and hemorrhagic stroke.11.4. ASA is not recommended in principle
However, ASA may be prescribed with concomitant use with
OACs for the following patients:a. Patients who developed thromboembolism despite favorable
compliance to treatment with OAC.b. Patients with a history of nonembolic cerebral infarction or TIA
who require treatment with antiplatelet agents.c. Patients complicated with ischemic heart disease.
d. Patients who had stenting.
11.5. Anticoagulation therapy for patients who undergo surgery and
other invasive procedures that cause bleeding
The risk of thromboembolism is low (0.5%) in patients who
discontinue dabigatran 2 days before or warfarin 5 days before the
surgery/procedure and restart them on the following day even
when they do not receive bridging therapy. Bridging therapy
should be considered for patients with a high risk for stroke.
Novel short-acting OACs should be used for patients expected to
undergo surgery or a procedure that causes bleeding.
11.6. Switch from warfarin to novel OACs
In patients with a TTR of ≥65%, the efﬁcacy of warfarin therapy
is equivalent to 150 mg bid dabigatran in terms of the prevention
of stroke. Although the incidence of ICH was lower in the
dabigatran group, the risk of major gastrointestinal bleeding was
twice higher than in those receiving warfarin. Novel OACs may not
be used in place of warfarin in patients with stable control of
anticoagulation with no bleeding complications.
11.7. Anticoagulant therapy for patients with paroxysmal AF
The risk of stroke in patients with paroxysmal AF is similar to
those in patients with persistent AF. Patients with paroxysmal AF
should thus undergo antithrombotic therapy similarly to those
with persistent AF.
11.8. OAC in patients receiving elective deﬁbrillation
International guidelines recommend that patients undergoing
elective deﬁbrillation should continue warfarin therapy for
3 weeks before and 4 weeks after deﬁbrillation. No evidence for
safety has been established in terms of the appropriate length
of treatment with novel OACs before and after deﬁbrillation,
although a subanalysis of the RE-LY trial [43] demonstrated that
the incidence of thromboembolism during the ﬁrst 30 days after
deﬁbrillation was low in patients receiving dabigatran.
11.9. Cost-effectiveness and others
We should also consider the cost-effectiveness of novel OACs.
In Japan, the National Health Insurance drug price of the average
daily dose of warfarin (3 mg/day) is 30 yen, whereas the corre-
sponding ﬁgure of dabigatran (150 mg bid) and rivaroxaban
(15 mg od) is about 500 yen, which places a signiﬁcant ﬁnancial
burden on patients. Physicians should select OACs for individual
patients by weighing the costs and the beneﬁts of using novel
OACs, which may avoid various problems associated with warfarin
therapy and decrease the risk of stroke and bleeding.
Physicians should also be aware that there are no speciﬁc
antidotes available for the treatment of bleeding complica-
tions caused by novel OACs. We hope that physicians will utilize
S. Ogawa et al. / Journal of Arrhythmia 29 (2013) 190–200200the present guidelines in their practice considering these facts
carefully.Conﬂict of interest
None.
References
[1] Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk
stratiﬁcation schemes to predict stroke in patients with nonvalvular atrial
ﬁbrillation. Stroke 2008;39:1901–19.
[2] Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the
management of patients with atrial ﬁbrillation: a report of the American
College of Cardiology/American Heart Association Task Force on practice
guidelines and the European Society of Cardiology Committee of practice
guidelines (Writing Committee to Revise the 2001 Guidelines for the Manage-
ment of Patients with Atrial Fibrillation): developed in collaboration with
European Heart Rhythm Association and the Heart Rhythm Society. Circula-
tion 2006;114:e257–354.
[3] You JJ, Singer DE, Howard PA, et al. American College of Chest Physicians.
Antithrombotic therapy for atrial ﬁbrillation: antithrombotic therapy and
prevention of thrombosis, 9th edition: American College of Chest Physicians
evidence-based clinical practice guidelines. Chest 2012;141:e531S–75.
[4] European Heart Rhythm Association. European Association for cardio-thoracic
surgery: guidelines for the management of atrial ﬁbrillation: the Task Force for
the Management of Atrial Fibrillation of the European Society of Cardiology
(ESC). Eur Heart J 2010;31:2369–429.
[5] Camm AJ, Lip GYH, Caterina RD, et al. Focused update of the ESC guidelines for
the management of atrial ﬁbrillation. Eur Heart J 2012;33:2719–47, http://dx.
doi.org/10.1093/eurheartj/ehs253.
[6] Department of Health, Western Australia. Quick reference guide: atrial
ﬁbrillation information for the health practitioner. Perth: Health Networks
Branch. Department of Health, Western Australia; 2011.
[7] Cairns JA, Connolly S, McMurtry S, et al. Canadian Cardiovascular Society atrial
ﬁbrillation guidelines 2010: prevention of stroke and systemic thromboem-
bolism in atrial ﬁbrillation and ﬂutter. Can J Cardiol 2011;27:74–90.
[8] Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian
Cardiovascular Society atrial ﬁbrillation guidelines: recommendations for
stroke prevention and rate/rhythm control. Can J Cardiol 2012;28:125–36.
[9] JCS Joint Working Group. Guidelines for pharmacotherapy of atrial ﬁbrillation
(JCS2008): digest version. Circ J 2010;74:2479–500.
[10] Ogawa S, Aonuma K, Huang D, et al. Fact-ﬁnding survey of antithrombotic
treatment for prevention of cerebral and systemic thromboembolism in
patients with non-valvular atrial ﬁbrillation in 9 countries of the Asia-Paciﬁc
region. J Arrhythmia 2012;28:41–55.
[11] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in
patients with atrial ﬁbrillation. N Engl J Med 2009;361:1139–51.
[12] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identiﬁed events in the RE-LY
trial. N Engl J Med 2010;363:1875–918.
[13] Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban
versus warfarin in nonvalvular atrial ﬁbrillation. N Engl J Med 2011;365:
883–91.
[14] Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in
patients with atrial ﬁbrillation. N Engl J Med 2011;365:981–92.
[15] Ogawa S, Hori M. Urgent statement on antithrombotic therapy of atrial
ﬁbrillation. Circ J 2011;75:2719–21.
[16] Olesen JB, Fauchier L, Lane DA, et al. Risk factors for stroke and thromboem-
bolism in relation to age among patients with atrial ﬁbrillation: the Loire
Valley Atrial Fibrillation Project. Chest 2012;141:147–53.
[17] Friberg L, Rosenqvist M, Lip GY. Net clinical beneﬁt of warfarin in patients with
AF. A report from the Swedish AF Cohort study. Circulation 2012;125:
2298–307.
[18] Banerjee A, Lane DA, Torp-Pederson C, et al. Net clinical beneﬁt of new oral
anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a
‘real world’ atrial ﬁbrillation population: a modelling analysis based on a
nationwide cohort study. Thromb Haemost 2012;107:584–9.
[19] Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of
dabigatran compared with warfarin in older and younger patients with atrialﬁbrillation: an analysis of the randomized evaluation of long-term antic-
oagulant therapy (RE-LY) trial. Circulation 2011;123:2363–72.
[20] Halperin JL, Wojdyla D, Piccini JP, et al. Efﬁcacy and safety of rivaroxaban
compared with warfarin among elderly patients with nonvalvular atrial
ﬁbrillation in the ROCKET-AF Trial [abstract]. Stroke 2012;43:A148.
[21] Singer DE, Chang Y, Fang MC, et al. The net clinical beneﬁt of warfarin
anticoagulation in atrial ﬁbrillation. Ann Intern Med 2009;151:297–305.
[22] Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of
stroke in low-risk patients with atrial ﬁbrillation: Japan Atrial Fibrillation
Stroke Trial. Stroke 2006;37:447–51.
[23] Shen AY, Yao JF, Brar SS, et al. Racial/ethnic differences in the risk of
intracranial hemorrhage among patients with atrial ﬁbrillation. JACC 2007;50:
309–15.
[24] Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and
bleeding with thromboprophylaxis in patients with atrial ﬁbrillation: a net
clinical beneﬁt analysis using a ‘real world’ nationwide cohort study. Thromb
Haemost 2011;106:739–49.
[25] Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory
patients with nonvalvular atrial ﬁbrillation: the Anticoagulation and
Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med 1999;131:
927–34.
[26] Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life
atrial ﬁbrillation patients: a report from the Euro Heart Survey on Atrial
Fibrillation. Eur Heart J 2006;27:3018–26.
[27] Waldo AL, Becker RC, Tapson VF, et al. Hospitalized patients with atrial
ﬁbrillation and a high risk of stroke are not being provided with adequate
anticoagulation. JACC 2005;46:1729–36.
[28] Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulation in
atrial ﬁbrillation: a systematic review. Am J Med 2010;123(638–45):e4.
[29] Cabral KP, Ansell J, Hylek EM. Future directions of stroke prevention in atrial
ﬁbrillation: the potential impact of novel anticoagulants and stroke risk
stratiﬁcation. J Thromb Haemost 2011;9:441–9.
[30] Garcia DA, Granger CB. Anticoagulation, novel agents, and procedures. Can we
pardon the interruption? Circulation 2012;126:255–7.
[31] Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and
thromboembolic events with dabigatran compared with warfarin. Results
from the Randomized Evaluation of Long-Term Anticoagulation Therapy
(RE-LY) randomized trial. Circulation 2012;126:343–8.
[32] Wahl MJ. Dental surgery in anticoagulated patients. Arch Intern Med 1998;
158:1610–6.
[33] Yasaka M, Naritomi H, Minematsu K, et al. Ischemic stroke associated with
brief cessation of warfarin. Thromb Res 2006;118:290–3.
[34] Evans IL, Sayers MS, Gibbons AJ, et al. Can warfarin be continued during
dental extraction? Result of a randomized controlled trial Br J Oral Maxillofac
Surg 2002;40:248–52.
[35] Ardekian L, Gaspar R, Peled M, et al. Does low-dose aspirin therapy
complicate oral surgical procedures? J Am Dent Assoc 2000;131:331–5.
[36] Dang M-TN, Hambleton J, Kayser SR. The inﬂuence of ethnicity on warfarin
dosage requirement. Ann Pharmacother 2005;39:1008–12.
[37] Yu HC, Chan TY, Critchley JA, et al. Factors determining the maintenance dose
of warfarin in Chinese patients. Q J Med 1996;89:127–35.
[38] You JH, Chan FW, Wong RS, et al. Is INR between 2.0 and 3.0 the optimal level
for Chinese patients on warfarin therapy for moderate-intensity anticoagula-
tion? Br J Clin Pharmacol 2005;59:582–7.
[39] Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international
normalized ratio in warfarin therapy for secondary prevention of stroke in
patients with non-valvular atrial ﬁbrillation. Intern Med 2001;40:1183–8.
[40] Hori M, Connolly SJ, Zhu J, et al. Efﬁcacy and safety of dabigatran versus
warfarin in patients with atrial ﬁbrillation: analysis in Asian population in RE-
LY trial. Cerebrovasc Dis 2012;34(Suppl 1):S6–4.
[41] Wallentin L, Yusuf S, Ezekowitz MD, et al. Efﬁcacy and safety of dabigatran
compared with warfarin at different levels of international normalized ratio
control for stroke prevention in atrial ﬁbrillation: an analysis of the RE-LY trial.
Lancet 2010;376:975–83.
[42] Wann LS, Curtis AB, Ellenbogen KA, et al. ACCF/AHA/HRS focused update on
the management of patients with atrial ﬁbrillation (update on dabigatran): a
report of the American College of Cardiology Foundation/American Heart
Association Task Force on practice guidelines. J Am Coll Cardiol 2011;57:
1330–7.
[43] Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in
patients with atrial ﬁbrillation: an analysis of patients undergoing cardiover-
sion. Circulation 2011;123:131–6.
